A 77-year-old man with a prolonged activated partial thromboplastin time

Clinical Chemistry

Volumn 58, Issue 10, 2012, Pages 1402-1407

  Ehrenschwender, Martin ^a,b   Koessler, Juergen ^a   Brunner, Kirsten ^a   Steigerwald, Udo ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 8; DABIGATRAN; DIGOXIN; DIURETIC AGENT; METFORMIN; METOPROLOL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE;

AGED; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DIURETIC THERAPY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; ENZYME ACTIVITY; HEART FAILURE; HEMATOMA; HOSPITAL ADMISSION; HUMAN; LIMIT OF DETECTION; MALE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PROTHROMBIN TIME; SKIN BRUISING; TREATMENT DURATION;

AGED; ANTICOAGULANTS; AUTOANTIBODIES; BENZIMIDAZOLES; BETA-ALANINE; DIAGNOSIS, DIFFERENTIAL; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME;

EID: 84867011827     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.168393     Document Type: Article

References (10)

1. Adcock D, Hoefner D, Kottke-Marchant K, Marlar A, Szamosi D, Warunek D. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assay and molecular hemostasis assays; approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
2. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
3. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(Suppl 1):9S-16S.
4. Stavrou E, Schmaier AH. Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010;125:210-5.
5. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-14. (Pubitemid 44403432)
6. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
7. Sahud MA. Laboratory diagnosis of inhibitors. Semin Thromb Hemost 2000;26:195-203. (Pubitemid 30439358)
8. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010;16:20-4.
9. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250-5.
10. Franchini M. Acquired hemophilia A. Hematology 2006;11:119-25. (Pubitemid 43840752)